The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, ...

This content is provided by Almac Group, and any views and opinions expressed do not necessarily reflect those of www.outsourcing-pharma.com Related categories: Analytical testing, QC Solid phase ...

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, shortly after successfully completing a first phase 1 clinical trial.

She brings her global experience across multiple therapeutic areas to her current role leading operations at YPrime. In this ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.